Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Dec;28(12):6119-6128.
doi: 10.1007/s00520-020-05706-4. Epub 2020 Aug 27.

Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of severe dermatological toxicities from checkpoint inhibitors

Jennifer Choi  1 , Ronald Anderson  2 , Ada Blidner  3 , Tim Cooksley  4   5 , Michael Dougan  6   7 , Ilya Glezerman  8 , Pamela Ginex  9 , Monica Girotra  10   11 , Dipti Gupta  11 , Douglas Johnson  12 , Vickie R Shannon  13 , Maria Suarez-Almazor  14 , Bernardo L Rapoport  15   16 , Mario E Lacouture  17
Affiliations
Review

Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of severe dermatological toxicities from checkpoint inhibitors

Jennifer Choi et al. Support Care Cancer. 2020 Dec.

Abstract

Immune checkpoint inhibitors (ICIs) frequently result in cutaneous immune-related adverse events (IrAEs). Although the majority of these events are mild-to-moderate in severity, up to 5% are severe, which may lead to morbidity and dose interruption or discontinuation of ICI therapy. In addition, up to 25% of dermatologic IrAEs are corticosteroid-refractory or corticosteroid-dependent. These 2020 MASCC recommendations cover the diagnosis and management of cutaneous IrAEs with a focus on moderate-to-severe and corticosteroid-resistant events. Although the usage of immune-suppressive therapy has been advocated in this setting, there is a lack of randomized clinical trial data to provide a compelling level of evidence of its therapeutic benefit.

Keywords: Bullous dermatoses; Corticosteroids; Cutaneous IrAEs; Inflammatory dermatitis; Pruritus; Skin rash; Vitiligo.

PubMed Disclaimer

Figures

Figure 1:
Figure 1:
Clinical phenotype of dermatologic Immune-Related Adverse Events (IrAEs): Maculopapular rash (left upper); Lichenoid rash (right upper); Eczematous (left lower); Bullous Pemphigoid (right lower).
Figure 2:
Figure 2:. Management of Dermatologic Immune-Related Adverse Events
MTX, methotrexate; CsA, cyclosporine A; MMF, Mycophenolate Mofetil; MPR, maculopapular rash; IL-6, interleukin-6; IgE immunoglobulin E.
See this image and copyright information in PMC

References

    1. Boutros C, Tarhini A, Routier E, Lambotte O, Ladurie FL, Carbonnel F, Izzeddine H, Marabelle A, Champiat S, Berdelou A, Lanoy E, Texier M, Libenciuc C, Eggermont AM, Soria JC, Mateus C, Robert C (2016) Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination. Nat Rev Clin Oncol 13(8):473–486. doi: 10.1038/nrclinonc.2016.58. - DOI - PubMed
    1. Puzanov I, Diab A, Abdallah K, Bingham CO 3rd, Brogdon C, Dadu R, Hamad L, Kim S, Lacouture ME, LeBoeuf NR, Lenihan D, Onofrei C, Shannon V, Sharma R, Silk AW, Skondra D, Suarez-Almazor ME, Wang Y, Wiley K, Kaufman HL, Ernstoff MS (2017) Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group. J Immunother Cancer 5(1):95. doi: 10.1186/s40425-017-0300-z. - DOI - PMC - PubMed
    1. Kumar V, Chaudhary N, Garg M, Floudas CS, Soni P, Chandra AB (2017) Current Diagnosis and Management of Immune Related Adverse Events (irAEs) Induced by Immune Checkpoint Inhibitor Therapy. Front Pharmacol 8:49. doi: 10.3389/fphar.2017.00049. - DOI - PMC - PubMed
    1. Hassel JC, Heinzerling L, Aberle J, Bähr O, Eigentler TK, Grimm MO, Grünwald V, Leipe J, Reinmuth N, Tietze JK, Trojan J, Zimmer L, Gutzmer R (2017) Combined immune checkpoint blockade (anti-PD-1/anti-CTLA-4): Evaluation and management of adverse drug reactions. Cancer Treat Rev 57:36–49. doi: 10.1016/j.ctrv.2017.05.003. - DOI - PubMed
    1. Haanen J, Carbonnel F, Robert C, Kerr KM, Peters S, Larkin J, Jordan K; ESMO Guidelines Committee (2017) Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 28(suppl_4):iv119–iv142. doi: 10.1093/annonc/mdx225. - DOI - PubMed

MeSH terms

Substances